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The medical importance of the human microbiome
The human intestine carries a vast and diverse microbial 
ecosystem that has co-evolved with our species and is 
essential  for  human  health  [1,2].  Mammals  possess  an 
‘extended genome’ of millions of microbial genes located 
in the intestine: the microbiome [3]. This multigenomic 
symbiosis is expressed at the proteomic and metabolic 
levels in the host and it has therefore been proposed that 
humans  represent  a  vastly  complex  biological  ‘super-
organism’  in  which  part  of  the  responsibility  for  host 
meta  bolic regulation is devolved to the microbial sym-
bionts [4]. Modern interpretation of the gut microbiome 
is based on a culture-independent, molecular view of the 
intestine provided by high-throughput genomic screen-
ing technologies [5,6]. Also, the gut microbiome has been 
directly implicated in the etiopathogenesis of a number 
of pathological states as diverse as obesity [7], circulatory 
disease [8], inflammatory bowel diseases (IBDs) [9] and 
autism [10] (Figure 1). The gut microbiota also influence 
drug metabolism and toxicity [11], dietary calorific bio-
availability  [12],  immune  system  conditioning  and  res-
ponse [13], and post-surgical recovery [14]. The implica-
tion is that quantitative analysis of the gut microbiome 
and its activities is essential for the generation of future 
personalized healthcare strategies [15] and that the gut 
microbiome represents a fertile ground for the develop-
ment of the next generation of therapeutic drug targets. 
It also implies that the gut microbiome may be directly 
modulated for the benefit of the host organism.
The gut microbiota therefore perform a large number 
of important roles that define the physiology of the host, 
such as immune system maturation [16], the intestinal 
response to epithelial cell injury [17], and xenobiotic [18] 
and energy metabolism [7]. In most mammals, the gut 
microbiome  is  dominated  by  four  bacterial  phyla  that 
perform these tasks: Firmicutes, Bacteroidetes, Actino-
bacteria and Proteobacteria [19]. The phylotype composi-
tion can be specific and stable in an individual [20], and 
in a 2-year interval an individual conserves over 60% of 
phylotypes of the gut microbiome [21]. This implies that 
each host has a unique biological relationship with its gut 
microbiota [22,23], and by definition that this influences 
an individual’s risk of disease. The gut microbiome varies 
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© 2011 BioMed Central Ltdbetween species and, as a result, in vivo models utilizing 
gnotobiotic rodents or pigs conventionalized with human 
baby  flora  (HBF)  have  been  adopted  to  permit  more 
accurate  modeling  of  the  human  gut  [24].  Future 
experimental models must also accurately replicate the 
metabolic function of the gut microbiome [25]. For this 
to occur, the ‘healthy’ intestinal microbiome must first be 
understood; for example, differences between individuals 
are  known  to  be  more  marked  among  infants  than  in 
adults [26], but later in life the gut microbiome converges 
to more similar phyla. It is not yet known how such an 
important symbiotic relationship, even in apparently well 
neonates,  influences  long-term  health  outcome.  There-
fore, there is now a significant effort to define a ‘core’ 
micro  biome  to  determine  the  role  played  by  the  gut 
micro  biome  in  diseases  across  geographically  diverse 
populations [6]. Here, we review recent studies that have 
provided important insights into the human gut micro-
biome, and the functional role of the gut microbiome in 
health, disease and in drug efficacy. We review current 
methods for the modulation of the gut microbiome for 
the  improvement  of  human  health  and  disease,  and 
Figure 1. Diseases influenced by gut microbial metabolism. The variety of systemic diseases that are directly influenced by gut microbial 
metabolism and its influence on other mammalian pathways, such as the innate immune system, are shown. Specifically highlighted are the 
metabolic pathways involved in drug metabolism and obesity that are directly influenced by the gut microbial content. Ags, antigens; C. bolteae, 
Clostridium bolteae; DCs; dendritic cells; SCFA, short-chain fatty acid; TLR, Toll-like receptor.
Gut-brain hypothesis
1. Autism
C. bolteae / clostridia spores
Mechanism unkown
2. Mood: depression, anxiety
 
Hygiene hypothesis:
Exagerrated innate immune response
Upregulation of regulatory T cells
after capture of Ags by DCs
Bifidobacteria, Gram +ve organisms
Clostridia
Peripheral vascular disease
Inflammatory bowel disease
Bacteroidetes and Actinobacteria in obese 
Altered energy / lipid metabolism
Higher relative abundance of glycoside hydrolases,
carbohydrate-binding modules,
glycosyltransferases, polysaccharide lyases, and carbohydrate 
esterases in the Bacteroidetes
TLR mediated  
Hypertension / 
ischemic
heart
disease
Biliary disease
Colon cancer
Altered xenobiotic / drug metabolism
Diet high in red meat and animal fat
Low SCFA / butyrate
High fecal fats
Low vitamin absorption
 7α dehydroxylating bacteria:
cholic aciddeoxycholic acid (co-carcinogen)
Low in H2S metabolizing bacteria
 
Obesity / metabolic syndrome
Asthma / atopy
e.g. Paracetamol metabolism:
  predose urinary p-cresol sulfate leads to  postdose urinary
acetaminophen sulfate :  acetaminophen glucuronide.
Bacterially mediated p-cresol generation and competitive
o-sulfonation of p-cresol reduces the effective systemic capacity
to sulfonate acetaminophen.
Hygiene hypothesis
Altered immune response: TLR signaling
Less microbial diversity
Activation of specific species: for example, Escherichia
Result of metabolic syndrome
Altered lipid deposition / 
metabolism
Altered enterohepatic circulation of bile
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this rapidly evolving area of research.
Recent insights into gut microbiome variation and 
activity
The advent of 16S rRNA gene-sequence-based methods 
[27] has led to the description of the substantial diversity 
of  the  gut  microbiome  between  healthy  individuals 
[28-30]. It has also led to new insights into the presence 
of particular species and strains in the human gut and 
their variance between intestinal locations and species of 
mammal. For example, 16S RNA approaches have been 
used to study the maturation of murine cecal microbiota, 
and  they  have  demonstrated  the  existence  of  a  large 
number of yet unidentified bacteria that inhabit it [31]. 
Such  ‘culture-independent’  techniques  are  used  to 
measure the stability of the microbiome over time and its 
stability when transferred between species. This is essen-
tial for building robust experimental models for the human 
microbiome and for delineating important mecha  nistic 
processes in the development of human disease states. 
Genomic  strategies,  such  as  denaturing  gradient  gel 
electrophoresis  (DGGE)  of  16S  rRNA  sequences,  have 
commonly been employed for this purpose. Analysis of 
human microbiota-associated (HMA) rat feces using this 
approach  has  revealed  that  the  Bacteroides/Prevotella 
and  Faecalibacterium  species  are  dominant  in  both 
humans and HMA rats post-transfection [32]. However, 
HMA rats also possessed Ruminococcus, which was not 
present in the human DGGE profile. With this exception, 
the  sequences  originating  from  both  rats  and  human 
samples were represented in all major branches of a non-
parametric statistical method for computational phylo-
genetics known as a maximum parsimony tree. Analysis 
of 16S rRNA analysis has also provided new insights into 
the  Cytophaga-Flavobacterium-Bacteroides  phylum, 
which  has  recently  been  found  to  be  common  to  the 
intestines of mice, rats and humans [33].
Recent advances in sequencing technologies have led to 
the  wider  use  of  metagenomic  analysis  for  studying 
complex ecosystems such as the human gut [34-36], and 
some key findings from human studies are outlined in 
Table 1. This approach functions on the principle that the 
genome sequences of abundant species will be well repre-
sented in a set of random shotgun reads, whereas species 
with  lower  abundance  may  be  represented  by  a  small 
number of sequences, thus permitting the comprehensive 
measurement  of  the  response  of  an  ecosystem  to  an 
environmental perturbation or therapeutic intervention. 
This technology brings with it the significant challenge of 
managing vast data sets. For example, in three separate 
studies 3 Gb of microbial sequences were generated from 
fecal  samples  of  only  33  individuals  from  the  USA  or 
Japan  [2,29,37].  Advances  in  analytical  approaches  are 
only exacerbating this problem and in a separate analysis 
576.7 Gb of sequence, almost 200 times more than in all 
previous  studies,  was  generated  using  an  IlluminaTM 
Genome Analyzer (Illumina, San Diego, CA, USA) for 
deep sequencing of total DNA from fecal samples of 124 
European adults (Table 1).
However, metagenomic sequencing of the gut micro-
biome has some limitations. The intestinal epithelium is 
composed of three functional barriers: a physical barrier, 
an  innate  immune  barrier  and  an  adaptive  immune 
barrier  [38].  The  relationship  between  commensal  gut 
flora and the intestinal barrier is complex, and occurs at 
each  of  these  interfaces,  and  fecal  metagenomics  does 
not  therefore  measure  ecosystem  changes  at  all  levels. 
Also,  metagenomic  analysis  of  fecal  samples  does  not 
provide a comprehensive picture of important molecular 
interactions within the complex topography and niches 
in  the  gut.  Nonetheless,  metagenomic  analysis  does 
permit some inference of functional information. Gill et 
al. [2] reported the variation between two individuals in 
the  distal  gut  metagenome.  The  authors  described 
statistically  significant  variability  in  the  enrichment  of 
several classes of genes involved in energy metabolism, 
carbohydrate, amino acid and nucleotide transport and 
co-enzyme  transport.  Clusters  of  orthologous  groups 
analysis also revealed the under-representation of genes 
involved  in  secondary  metabolite  biosynthesis,  and 
inorganic  ion  transport  and  metabolism  in  the  human 
distal gut microbiome (Table 1). This suggested that there 
is significant interindividual and interspecies variability.
The key aim of the majority of this work has therefore 
been  to  try  and  define  a  ‘core  microbiome’.  This  is  an 
important  aim,  as  it  implies  that  we  all  share  a  key 
number of essential species or strains that help to define 
human health and, more importantly, that can then be 
mined  for  drug  targets.  Data  from  these  studies  have 
been  conflicting  on  this  point.  Turnbaugh  et  al.  [39] 
recently  concluded  that  a  core  microbiome  based  on 
species or strain data may not be present, because their 
data demonstrated that by adulthood no single bacterial 
phylotype was detectable at an abundant frequency in the 
guts  of  all  154  humans  sampled  in  their  metagenome 
wide study. Qin et al. [6] reported the definition of the 
minimal  core  microbiome:  576.7  Gb  were  sequenced 
from  124  individuals,  and  this  demonstrated  that  18 
species  were  found  in  all  individuals;  57  species  were 
demonstrated in ≥90% of the study cohort, and 75 species 
were found in ≥50% of the study cohort. However, this 
may reflect a different analytical approach, and this study 
also employed a cohort of patients with IBD. Therefore, it 
may be that the gut pathology aligns the gut microbiota, 
and reduces the variability found in a healthier populace. 
Turnbaugh  et  al.  have  argued  that  a  core  microbiome 
may exist at a functional level (for example at a genomic, 
Kinross et al. Genome Medicine 2011, 3:14 
http://genomemedicine.com/content/3/3/14
Page 3 of 12Table 1. Human metagenomic studies that have studied the distal gut microbiome
Study
Number of 
humans
Sequencing 
technology Sequence length Phylogenetic data and key findings
Gene function (for example, KEGG/COG-
enriched processes) 
Gill et al. 
(2006) [2]
2 (1 male, 
1 female, 
healthy)
ABI 3730xl 
sequencer 
(Applied 
Biosystems)
17,668 contigs; 
14,572 scaffolds; 
33,753,108 bp; 
50,164 ORFs; 
19,866 unique 
database matches 
predicted
72 bacterial phylotypes identified; 1 
archaeal phylotype (Methanobrevibacter 
smithii); 16 novel bacterial phylotypes.
Phylotypes assigned: Firmicutes (62 
phylotypes, 105 sequences) and the 
Actinobacteria (10 phylotypes, 27 
sequences)
Energy production and conversion; carbohydrate 
transport and metabolism; amino acid transport 
and metabolism; coenzyme transport and 
metabolism; secondary metabolites biosynthesis, 
and transport and catabolism; MEP pathway for 
biosynthesis of DXP and IPP; β-glucuronidase 
activity induced
Kurokawa 
et al. (2007) 
[37]
7 adults, 
2 children 
and 4 
unweaned 
infants 
(Japanese 
and 
Japanese 
American)
ABI 3730 
sequencers 
(Applied 
Biosystems) 
or the ET 
chemistry on 
MegaBACE4500 
sequencers (GE 
Healthcare)
1,057,481 shotgun 
reads representing 
sequences of 727 
Mb; total length 
of the contigs 
and singletons 
from 13 samples 
was 478.8 Mb; 
identified 20,063 
to 67,740 potential 
protein-encoding 
genes
17% to 43% of predicted genes 
assigned to particular genera (35 to 65 
genera, 121 in total). 
Adults and weaned children: 
Bacteroides and genera belonging 
to division Firmicutes (for example, 
Eubacterium, Ruminococcus 
and Clostridium, and the genus 
Bifidobacterium. Infants: Bifidobacterium 
and/or a few genera from the family 
Enterobacteriaceae, such as Escherichia, 
Raoultella and Klebsiella
Carbohydrate transport and metabolism; 
under-representation of those for ‘lipid transport 
and metabolism’; defense mechanisms; cell 
motility, secondary metabolites biosynthesis, 
transport and catabolism and post-translational 
modification and protein turnover; pyruvate-
formate lyase enriched; formate hydrogenlyase 
system under-represented 
Turnbaugh 
et al. 2009 
[39,100]
154 (31 
MZ and 23 
DZ female 
twin pairs 
and their 
mothers 
n = 46, 
twins 
concordant 
for obesity 
or leanness)
454 
Pyrosequencing
9,920 near 
full-length and 
1,937,461 partial 
bacterial 16S rRNA 
sequences
Gut microbiome shared among family 
members; degree of co-variation 
between adult MZ and DZ twin pairs; 
no single abundant bacterial species 
shared by all 154 individuals; wide array 
of shared microbial genes in sampled 
general population: ‘core microbiome’ 
at the gene level. 
Lower proportion of Bacteroidetes and 
a higher proportion of Actinobacteria 
in obese subjects and reduced bacterial 
diversity. Altered representation 
of bacterial genes and metabolic 
pathways, including those involved in 
nutrient harvest
Total of 156 total CAZy families found within at 
least one human gut microbiome: 77 glycoside 
hydrolase, 21 carbohydrate-binding module, 35 
glycosyltransferase, 12 polysaccharide lyase, 11 
carbohydrate-esterase families. Carbohydrate 
metabolism pathways enriched in Bacteroidetes 
bins; transport systems in Firmicutes bins; 
transcription and translation pathways enriched; 
carbohydrate and amino acid metabolism; 
secretion systems, and membrane transport for 
import of nutrients, including sugars varied in 
their enrichment
Qin et al. 
(2010) [6]
124 healthy, 
overweight 
and obese 
individual 
human 
adults; 21 
ulcerative 
colitis, 4 
Crohn’s 
disease
Illumina GA 6.58 million 
contigs (>500 
bp giving a total 
contig length of 
10.3 Gb); 576.7 Gb
Definition of minimal core microbiome: 
at 1% (40 kb) coverage, 18 species 
in all individuals, 57 in ≥90% and 75 
in ≥50% of individuals; 99.96% of 
the phylogenetically assigned genes 
belonged to the bacteria and archaea. 
Bacteroidetes and Firmicutes had the 
highest abundance. 
Network analysis of 155 species 
in at least one individual at ≥1% 
coverage had prominent clusters for 
Bacteroidetes, Dorea/Eubacterium/
Ruminococcus, Bifidobacteria, 
Proteobacteria and streptococci/
lactobacilli groups
Genes related to adhesion and harvesting sugars 
of the globoseries glycolipids; phage-related 
proteins; biodegradation of complex sugars and 
glycans, for example, pectin (and its monomer, 
rhamnose) and sorbitol; three-quarters of 
prevalent gut functionalities from novel gene 
families; approximately 45% of functions present 
in <10% of the sequenced bacterial genomes
Koenig et al. 
[101]
1 infant 
over 
2.5 years 
454 
pyrosequencing
318,620 16S rRNA 
gene sequences
Phylogenetic diversity correlates with 
age. Diversity changed gradually in 
four discrete phases: (1) days 1 to 92: 
Firmicute OTUs; (2) fever at day 92: 
proteobacterial and actinobacterial 
OTU abundances, suite of Firmicute 
OTUs differed; (3) exclusion of breast 
milk; and (4) introduction of peas and 
cefdinir use: increase in Bacteroidetes
Carbohydrate metabolism; amylose, arabinose 
and maltose degradation; virulence genes 
enriched; rhamnose, fructo-oligosaccahride 
and raffinose-utilization pathways, and xylose-
degradation genes expressed; lactose/galactose 
and sucrose utilization; antibiotic resistance; 
vitamin biosynthesis; sialic acid metabolism, 
β-glucoronide utilization; polysaccharide 
metabolism (day 371: maltose, maltodextrin, 
xylose); xenobiotic degradation; benzoate 
catabolism and aromatic metabolism
Summary of the key experimental findings and the predominant phylogenetic data, and specific pathways and functional pathways highlighted by analysis from the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and clusters of orthologous groups (COG) analysis. CAZy, carbohydrate-active enzyme; DZ, dizygotic; 
DXP, deoxyxylulose 5-phosphate; IPP, isopenteryl pyrophosphate; MEP, 2-methyl-d-erythritol 4-phosphate; MZ, monozygotic; OUT, operational taxonomic unit. 
Applied Biosystems, Carlsbad, CA, USA; GE Healthcare, Piscataway, NJ, USA; Illumina, San Diego, CA, USA.
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may be required for its further analysis. It also suggests 
that from a systems perspective we are highly variable 
with  tremendous  implications  for  personalized  health-
care strategies. A key question now is: how is this unique 
ecosystem assembled and maintained within individuals 
or across species?
Initial metagenomic analysis seems to confirm the sta-
bility of some microbial species between animal species. 
Fecal DNA samples from dogs were analyzed using 454 
pyrosequencing [40]. Sequenced data were interpreted by 
the  Meta  Genome  Rapid  Annotation  using  Subsystem 
Technology  (MG-RAST  [41])  and  this  was  compared 
with paired data from lean and obese mouse cecal meta-
genomes  [7]  and  two  human  fecal  metagenomes  (F1S; 
HSM) [37]. The Bacteroidetes/Chlorobi and Firmicutes 
phyla  comprised  35%  of  all  sequences,  followed  by 
Proteobacteria (13% to 15%) and Fusobacterium (7% to 
8%).  Hierarchical  clustering  of  several  gastrointestinal 
meta  genomes demonstrated phylogenetic and metabolic 
similarity between dogs, humans and mice.
Metagenomic approaches are not just restricted to the 
analysis of microbial genomes. A more novel area of work 
relates  to  the  analysis  of  the  interaction  of  the  gut 
microbiome with gut parasites, viruses, yeasts and fungi, 
and its importance for human health [42]. Fungal inter-
actions  with  the  distal  gut  microbiome  have  yet  to  be 
characterized  using  a  metagenomic  analysis,  although 
this  has  been  attempted  within  the  oral  microbiome 
using a multitag pyrosequencing approach in 20 healthy 
individuals  [43].  However,  the  gut  virome  has  recently 
been  investigated.  Fecal  samples  were  collected  from 
healthy adult female monozygotic twins and their mothers 
at  three  time  points  over  a  1-year  period  [44].  These 
datasets  were  compared  with  datasets  of  sequenced 
bacterial  16S  rRNA  genes  and  total-fecal-community 
DNA.  In  keeping  with  other  studies  reported  in  the 
literature, twins and their mothers share a significantly 
greater  degree  of  similarity  in  their  fecal  bacterial 
communities when compared with unrelated individuals. 
However, viromes were found to be unique to individuals 
regardless of their degree of genetic relatedness. Further-
more, intrapersonal diversity was very low, with 95% of 
virotypes  retained  over  the  period  surveyed.  These 
results suggested that the viral-microbial dynamic found 
in  other  environmental  ecosystems  was  not  present  in 
the very distal intestine. This area of research is likely to 
become increasingly important as more of the interking-
dom signaling pathways are elucidated, and the impor-
tance  of  viral,  parasite  and  fungal  mutualism  is  recog-
nized. Metagenomics therefore represents a growing and 
important area of research into the gut microbiome, and 
work in this area continues to generate new, potentially 
important taxa that are being described [45].
The functional role of the gut microbiome in 
health, disease and drug efficacy
Culture-independent genomic strategies are not without 
limitations because of their inability to infer organismal 
function from these gene sequences. A genomic strategy 
will  therefore  largely  only  describe  the  potential  for  a 
disease  state.  Hybrid  approaches  are  thus  required  to 
provide temporal information about the actual biological 
activity of the microbiome. Approaches such as proteo-
mics and metabonomics can thus be used to study the 
functional capacity of the gut microbiome from the top 
down [46,47]. Real time analysis of the intestinal micro-
biome  is  essential  for  both  the  development  and  the 
monitor  ing  of  interventional  personalized  therapeutic 
strategies.  Metabonomics  describes  the  computational 
analysis of spectral metabolic data to provide information 
on  time-specific  metabolic  changes  across  a  complex 
system [48]. In turn, this has led to the concept of ‘global 
metabolic profiling’, which provides a unique overview of 
the metabolic state of an individual. This is because it is 
able  to  indirectly  measure  complex  transgenomic  co-
metabolic  interactions  that  are  vital  for  human  health, 
and which are often modulated by disease [49,50]. The 
notion of microbial-mammalian metabolic cooperation is 
defined through the concept of the human metabonome 
(the  sums  and  interactions  of  all  the  cellular  metabo-
lomes) [51]. Metabolic profiling coupled with the meta-
genomic study of the gut microbiota permits the close 
inter-relationship  between  the  host  and  microbial 
‘metabotypes’ to be studied in great detail, and provides 
the basis for further understanding the microbial-mam-
malian metabolic axis. Ultimately, this has led to the idea 
of ‘functional metagenomics’, defined as ‘the characteri-
zation of key functional members of the microbiome that 
most influence host metabolism and hence health’ [52].
Metabolic profiling strategies, such as high-throughput 
analysis by NMR spectroscopy or mass spectrometry, are 
widely  used  to  provide  global  metabolic  overviews  of 
human  metabolism  [8,47,48,53-55].  These  methods  are 
used  in  conjunction  with  computational  multivariate 
analysis  to  provide  a  deeper  understanding  of  disease 
states and biomarker discovery. This approach allows the 
quantification  of  environmental  influences  on  the  host 
genome  and  human  health  [48,55].  This  analytical 
strategy  has  now  been  successfully  applied  to  disease 
states such as hypertension [8], ischemic heart disease 
[56], diabetes [57] and obesity [58] as part of large-scale 
clinical studies. These studies suggest that the intestinal 
microbiome  is  essential  in  determining  the  metabolic 
response of the host to environmental stimuli and thus 
disease. Moreover, the intestinal microbiome is essential 
for  determining  the  toxic  response  to  pharmacological 
therapies, and the case of paracetamol permits pre-dose 
predictions of toxicity to be made [18,59].
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of aqueous fecal extracts across humans, mice and rats 
has been performed using high-resolution NMR spectro-
scopy [60]. Although many fecal metabolites are common 
to  the  three  species,  such  as  short-chain  fatty  acids 
(SCFAs)  and  branched  chain  amino  acids,  each  host 
species  generates  a  unique  metabolic  profile  when 
analyzed by multivariate analysis. This analysis refers to a 
suite of unsupervised (for example, principal component 
analysis)  or  supervised  methods  (for  example,  partial 
least squares discriminant analysis) for analyzing large-
scale spectroscopic data sets.
The biochemical composition of intact intestinal tissues 
(duodenum,  jejunum,  ileum,  and  proximal  and  distal 
colon)  has  recently  been  studied  in  germ-free  mice 
inocu  lated  with  human  baby  microbiota,  using  magic-
angle-spinning NMR spectroscopy. The HBF-inoculated 
tissue metabolite profiles were then compared with those 
from conventional (that is, gnotobiotic mice transfected 
with normal mouse intestinal flora) and conventionalized 
mice  (gnotobiotic  mice  transfected  with  HBF).  This 
demon  strated  that  biochemical  topographical  variation 
exists between intestinal regions that are specific for the 
microbiomes. In particular, osmolytes were affected and 
the  duodenum  had  higher  ethanolamine  and  myo-
inositol quantities, and the ileum had higher taurine and 
betaine levels than other gut regions. HBF mice showed 
lower taurine and myo-inositol levels in the colon, and all 
ex-germfree  animals  had  higher  taurine,  choline  and 
ethano  lamine  levels  in  the  jejunum.  Interestingly,  the 
jejunum of HBF mice was marked by a higher glutathione 
level and lower concentrations of its precursor methio-
nine when compared with other groups [61].
Top-down  multivariate  analysis  of  metabolic  profiles 
also reveals a significant association of specific metabo-
types with the resident microbiome. Martin et al. [62] 
derived a transgenomic graph model showing that HBF 
has a remarkably simple microbiome/metabolome corre-
la  tion network, impacting directly on the ability of the 
host to metabolize lipids, and fundamentally altering the 
biliary enterohepatic circulation. This effect can also be 
measured in plasma using an approach based on mass 
spectrometry [54]. The production of indole-3-propionic 
acid  was  shown  to  be  completely  dependent  on  the 
presence of gut microflora, and could be established by 
colonization with the bacterium Clostridium sporogenes. 
Multiple  organic  acids  containing  phenyl  groups  were 
also greatly increased in the presence of gut microbes. 
More interestingly, a broad, phase II metabolic response 
of the host to metabolites generated by the microbiome 
was observed, suggesting that the gut microflora have a 
direct impact on drug metabolism.
This variation between individuals continues at a pro-
teomic  level.  A  non-targeted,  shotgun  mass-spectro-
metry-based  whole  community  proteomics,  or  meta-
proteo  mics, approach has been used for measurements 
of thousands of proteins in human fecal samples taken 
from  two  monozygotic  twins.  Analysis  was  performed 
using  two-dimensional  liquid  chromato  graphy-mass 
spectrometry/mass  spectrometry  [47].  In  contrast  to 
metagenomic data sets, the metaproteome had relatively 
more of its distribution attributed to translation, energy 
production and carbohydrate metabolism. Antimicrobial 
peptides were also identified, suggesting that the mam-
malian response to the gut microbiome can also be quan-
tified. Several unknown proteins were also described for 
microbial pathways or host immune responses, revealing 
a novel complex interplay between the human host and 
its associated microbes. However, a significant problem 
arises  with  proteomic  analysis,  and  this  is  that  the 
number of unknown proteins far outweighs the number 
of unknown genes. This is likely to serve as a significant 
bottleneck in the functional use of proteomic data for use 
in future analysis of the gut microbiome.
The effect of the gut microbiota on drug metabolism 
has been previously explored, and the metabolic pathway 
of several drugs, such as l-DOPA, sulfasalazine, digoxin 
and even glyceryl trinitrate, has been established in the 
gut [63]. However, metabonomic approaches are creating 
new insights into commonly prescribed drugs, such as 
simvastatin, that were not previously appreciated. This is 
the most commonly prescribed statin in a billion dollar 
global market. It serves as an inhibitor of 3-hydroxy-3-
methylglutaryl  coenzyme  A,  regulating  hepatic  choles-
terol production. Simvastatin is degraded in the gut by 
hydrolytic  cleavage  of  methylbutanoic  acid  from  its 
backbone. Metabolism involves gut microbial processes 
of the demethylation of dimethylbutanoic acid, hydroxy-
lation/dehydroxylation and β-oxidation, resulting in the 
production  of  2-hydroxyisovaleric  acid  (3-methyl-2-
hydroxy  butanoic acid), 3-hydroxybutanoic acid and lactic 
acid (2-hydroxypropanoic acid), and finally re-cyclization 
of heptanoic acid to produce cyclohexanecarboxylic acid 
[64]. The implication is significant, as there may be much 
greater  variability  of  statin  drug  metabolism  between 
individuals than is currently appreciated, and this serves 
as  an  example  for  the  need  for  better  personalized 
approaches to drug development.
Several disease states are now being linked with patho-
logical variation in the gut microbiome using functional 
approaches  such  as  metabonomics  or  proteomics  and 
metagenome level analysis.
An  exploration  of  the  dominant  bacteria  in  patients 
with  colorectal  cancer  (CRC)  was  recently  undertaken 
[65].  A  significantly  reduced  temporal  stability  and  in-
creased diversity for the microbiota of subjects with CRC 
and  polyposis  was  found  using  a  16S  rDNA  DGGE 
analysis.  A  significantly  increased  diversity  of  the 
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was also noted for both disease groups. A clear division 
in  the  metabonome  was  observed  for  the  CRC  and 
polypectomized subjects compared with control volun-
teers. The production of hydrogen sulfide, an end product 
of metabolism by the sulfate-reducing bacteria, has been 
cited as a potential etiological agent in gastrointestinal 
disease.  Hydrogen  sulfide  has  genotoxic,  cytotoxic  and 
inflammatory  effects,  and  its  inefficient  metabolism  by 
species of sulfate-reducing bacteria could have a critical 
impact on the health of the host. Therefore, in a separate 
study, the same authors used quantitative PCR to study a 
cohort  of  CRC  and  polypectomized  patients.  CRC 
patients had significantly lower numbers of Desulfovibrio 
species  than  healthy  individuals,  suggesting  a  possible 
new role for the gut bacteria in the mechanism of CRC.
Bacterial genes involved in regulation of NF-κB signaling 
in intestinal epithelial cells have been described recently 
using  a  HT-29  cell  line,  transfected  with  a  plasmid 
containing the secreted alkaline phosphatase gene under 
the control of NF-κB binding elements [66]. Screening of 
2,640 metagenomic clones led to the identi  fication of 171 
modulating  clones  and,  among  these,  one  stimulatory 
metagenomic clone, 52B7, was sequenced. This suggested 
that the metagenomic DNA insert might belong to a new 
Bacteroides strain, and two loci encoding an ATP-binding 
cassette  transport  system  and  a  putative  lipoprotein  are 
potentially involved in the 52B7 effect on NF-κB.
The gut microbiome has been extensively linked with 
IBD,  and  recently  the  ‘hygiene  hypothesis’  has  been 
implicated;  this  suggests  that  a  reduction  in  microbial 
exposure  as  a  result  of  improved  health  measures  has 
contributed to an immunological imbalance in the intes-
tine,  and  has  increased  the  incidence  of  autoimmune 
diseases  such  as  IBDs  [67].  Culture-independent  tech-
niques  are  also  providing  new  information  on  the  gut 
ecology  of  these  conditions.  Specific  bacterial  popula-
tions  are  activated  in  patients  with  IBD,  while  other 
groups are in an inactive or ‘dormant’ state, such as the 
Actinobacteria and Firmicutes, while Escherichia species 
have been found to be both abundant and active in the 
Crohn’s disease and ulcerative colitis groups [68]. Pseudo-
monas  species  are  also  less  diverse  in  Crohn’s  disease 
patients compared with non-IBD patients. In particular 
Pseudomonas aeruginosa was only identified in non-IBD 
patients  [69].  Irrespective,  there  is  increasing  evidence 
that  the  microbiome  is  able  to  directly  influence  the 
expression of the innate immune system via the Toll-like 
receptor  (TLR)  pathway  [70].  Commensal  bacteria  are 
also  vital  for  modulating  the  immune  response,  and 
SCFAs appear to be central to this process. New mecha-
nisms of action for these important metabolites are being 
found;  for  example,  SCFAs  bind  to  the  G-coupled-
protein-receptor  43  and  this  is  necessary  for  the 
resolution  of  certain  inflammatory  responses  [71].  The 
hygiene hypothesis has therefore also been implicated in 
the etiology of asthma and atopy via a mechanism similar 
to that of the modulation of the innate immune response 
[72,73] (Figure 1).
The  concept  that  intestinal  microbial  composition 
affects the health of the gut, and also influences centrally 
mediated systems involved in mood and mental health, is 
being increasingly reported. This is described by the gut-
brain communication hypothesis, and it is possible that 
the  gut  microbiota  have  a  role  in  the  pathogenesis  of 
psychiatric  disorders  such  as  depression,  particularly 
when  linked  to  conditions  such  as  IBD  [74].  Animal 
studies have provided evidence to suggest a modulating 
role  for  probiotic  bacteria  in  immune,  neuroendocrine 
and neurochemical responses outside the gastrointestinal 
tract  [75].  Specifically,  the  absence  of  gastrointestinal 
microbes in mice results in reduced production of brain-
derived  neurotrophic  factor  in  the  cortex  and  hippo-
campus,  and  an  exaggerated  hypothalamic-pituitary-
adrenal  axis  response  to  stress  [76].  A  particularly 
interesting  avenue  of  research  has  focused  on  the 
potential role of the gut microbiota in the mechanism of 
autism. Clostridium bolteae is significantly more preva-
lent in the gut of autistic children [77], and although the 
mechanism by which gut flora are able to initiate autism 
is as yet not elucidated, it has been hypothesized that this 
pathway may be of importance [10].
Gut microbiome ‘transplantation’
Previous studies have confirmed that transplanted micro-
biota may be able to maintain their ecological stability in 
the host animal for 6 months [78] to 1 year [79]. This 
suggests that these models are robust enough to study 
the mechanism of human diseases, at least in the acute 
phase,  although  it  is  not  yet  known  if  this  approach 
accurately reflects the importance of the gut microbiota 
to human health over a period of ‘years’. However, short- 
to  medium-term  stability  means  that  the  metabolic 
potential  of  the  gut  microbiome  can  be  harnessed  for 
beneficial purposes, such as the treatment of antibiotic-
associated  diarrhea.  However,  this  approach  does  not 
always generate a positive outcome for the host. Such an 
effect  was  first  reported  by  Turnbaugh  et  al.  [7],  who 
demon  strated  that  the  obesity  phenotype  was  trans-
ferable after feces from obese mice were transferred to 
lean  animals.  Moreover,  the  same  altered  microbiome 
was demonstrated in a human study of obesity in lean 
and obese twins [29]. The transfer of cholesterol metabo-
lism characteristics has also been demonstrated in germ-
free rats. Gerard et al. [80] studied two groups of six, 
initially  germ-free,  rats  associated  with  two  groups  of 
different  human  microbiota,  which  exhibited  high  and 
low  cholesterol-reducing  activities.  Four  months  after 
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bacterial population level and exhibited coprostanoligenic 
activities  similar  to  those  of  the  corresponding 
human donor.
Deep sequencing and phylogenetic clustering has been 
used  to  examine  the  long-term  effects  of  exogenous 
micro  biota transplantation combined with and without 
an antibiotic pretreatment [81]. As a result of transplan-
tation, the intestinal bacterial diversity exceeded that of 
the human gut by a factor of two to three because of the 
capture of new phylotypes and an increase in abundance 
of others. However, antibiotic dosing prior to transplan-
ta  tion does not increase the establishment of the donor 
phylotypes, although some dominant lineages still trans-
ferred  successfully.  These  effects  were  observed  after 
1 month of treatment, and persisted after 3 months. The 
authors concluded the gut microbial ‘plasticity’ is con-
ditioned by the altered microbiome and that altered gut 
homeostasis  was  caused  by  antibiotic  pretreatment 
rather than by the primary bacterial loss. This is corro-
borated  by  top-down  systems  metabolism  approaches, 
which suggest a significant effect of antibiotics on host 
metabolism. Female mice dosed with oral vancomycin, 
and characterized using NMR spectroscopy of urine and 
fecal extract samples [82], demonstrated a higher fecal 
excretion of uracil, amino acids and SCFAs, highlighting 
the contribution of the gut microbiota to the production 
and metabolism of these dietary compounds. Compari-
son of urinary hippurate and phenylacetylglycine concen-
tra  tions to the fecal metabolite profile revealed a strong 
association between these urinary metabolites and a wide 
range  of  fecal  metabolites,  suggesting  a  causal  link 
between antibiotic use and an altered metabonome [83].
However,  gut  microbial  modulation  is  not  always 
initiated by medical intervention, and small bowel trans-
plants used in cases of intestinal failure permit an oppor-
tunity for long-term study of the microbial ecology of the 
human  small  bowel.  This  is  because  an  ileostomy  is 
created during surgery for monitoring the progress of the 
allograft  and  this  provides  access  to  samples  of  ileal 
effluent  and  mucosal  biopsies.  Seventeen  patients  with 
small  bowel  transplants  were  recently  studied  over  a 
period  of  8  weeks  and  they  had  their  ileal  content 
measured by quantitative PCR [52]. This demonstrated a 
form of microbial ‘metaplasia’ , where the normally strict 
anaerobic  Bacteroides  and  Clostridium  species  were 
replaced  by  Lactobacillus  and  Enterobacteriacae,  which 
are typically facultative anaerobes. After surgical closure of 
the  ileostomy,  the  community  reverted  to  the  normal 
structure.  Metabonomic  profiling  demonstrated  enrich-
ment for metabolites associated with aerobic respiration in 
samples from patients with open ileostomies, supporting 
the hypothesis that oxygen exposure was responsible for 
the change [53].
Therapeutic implications of gut microbiome 
modulation
The potential therapeutic role of the gut microbiota for 
human health has led to therapeutic approaches such as 
bacteriotherapy  [83]  and  bioecological  control  [84]. 
Broadly, these theories argue that modulation of intes-
tinal  floral  populations  either  by  the  pre-morbid  gut 
microbiota of the host or by prebiotics, probiotics and 
synbiotics  may  be  beneficial  for  human  health  [85]. 
Several  studies  now  suggest  that  fecal  transplantation 
may be beneficial in states of antibiotic-associated diar-
rhea or Clostridium difficile infection [86-88]. However, 
the long-term functional or metabolic consequences for 
the host of microbial modulation are poorly understood. 
New insights are being provided through the analysis of 
probiotic  and  prebiotic  studies  using  global  metabolic 
profiling  techniques,  where  evidence  suggests  that  the 
effect  may  be  cumulative  [45,89].  The  effects  of  the 
probiotics Lactobacillus paracasei or Lactobacillus rham-
nosus,  and  two  galactosyl-oligosaccharide  prebiotics, 
were  studied  in  germ-free  mice  inoculated  with  HBF. 
When  the  therapies  were  combined,  populations  of 
Bifidobacterium  longum  and  Bifidobacterium  breve 
increased, and Clostridium perfringens decreased. These 
microbial effects were associated with modulation of a 
range of host metabolic pathways indicated by changes in 
lipid  profiles,  gluconeogenesis,  and  amino  acid  and 
methylamine metabolism, and were associated with fer-
men  tation of carbohydrates by different bacterial strains. 
Hierarchical-principal  component  analysis  also  permit-
ted  the  visualization  of  multicompartmental  trans-
genomic metabolic interactions that were also resolved at 
the  compartment  and  pathway  level.  More  novel 
approaches that incorporate parasites that interact with 
the gut microbiome have also been suggested, such as the 
use of helminths in IBD [90].
Probiotic therapies have now been proposed for a large 
variety of gut-related disorders such as IBD, inflammatory 
bowel  syndrome  and  pouchitis  after  surgery  for  IBD. 
However, there are more novel areas of potential appli-
cation. A recent study assessed the potential benefits of 
the probiotic Bifidobacterium infantis in the rat maternal 
separation  model  [91].  Maternal  separation  adult  rat 
offspring were chronically treated with bifido  bacteria or 
citalopram  and  subjected  to  the  forced  swim  test  to 
assess motivational state. Probiotic treatment resulted in 
normalization  of  the  immune  response,  reversal  of 
behavioral deficits after maternal separation and a forced 
swim test, and restoration of basal nor  adrenaline concen-
trations in the brainstem.
It is highly likely that more detailed information on the 
ecology of the gut will lead to more medical targets for 
colonic and systemic disease states. The first evidence of 
this  approach  is  now  emerging,  as  drugs  may  also  be 
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essential  microbial  symbiotes  to  enhance  chemothera-
peutic  efficacy.  Recently,  a  novel  approach  has  been 
described  through  bacterial  modulation  of  the  dose-
limiting side effect of the common colon cancer chemo-
therapeutic  CPT-11.  This  commonly  causes  severe 
diarrhea  by  reactivation  of  the  symbiotic  bacterial  β-
glucuronidases in the gut. Potent bacterial β-glucuroni-
dase inhibitors have been identified by high-throughput 
screening  and  been  shown  to  have  no  effect  on  the 
orthologous  mammalian  enzyme  [92].  Inhibitors  were 
highly  effective  against  the  enzyme  target  in  living 
aerobic  and  anaerobic  bacteria,  but  did  not  kill  the 
bacteria or harm mammalian cells and oral adminis  tra-
tion of an inhibitor protected mice from CPT-11-induced 
toxicity. This suggests that the creation of personalized 
strategies for altering drug toxicity is readily achievable. 
This  is  corroborated  by  clinical  trials  showing  that 
probiotics  such  as  Bifidobacterium  and  Lactobacillus 
improve mood and reduce anxiety symptoms in patients 
with chronic fatigue syndrome and inflammatory bowel 
syndrome [76].
The concept of ‘personalized’ health care is therefore 
totally dependent on a better understanding of the gut 
microbiome  from  the  top  down  and  the  bottom  up 
[25,93]. Single probiotic agents are unlikely to dramati-
cally alter long-term health across populations without 
targeted interventions based on a prior knowledge of the 
microbial requirements of a specific person. This is even 
more important in the diseased gut, where the ecosystem 
may already be deleteriously affected. Even the effective 
delivery  of  engineered  bacteria  for  the  delivery  of 
endogenous therapeutic agents, which has been proposed 
for conditions such as IBD [94], will be dependent on a 
predictable ecosystem.
Bariatric  surgery  aims  to  reduce  the  volume  of  the 
stomach and increase transit times of food by diverting 
the flow of small bowel effluent through a gastric bypass 
procedure. Recently, 184,094 sequences of microbial 16S 
rRNA genes from PCR amplicons were examined using 
the  454  pyrosequencing  technology  to  compare  the 
micro  bial  community  structures  of  nine  individuals: 
three in each of the categories of normal weight, morbidly 
obese, and post-gastric-bypass surgery [95]. Phylogenetic 
analysis demonstrated that although the bacteria in the 
human  intestinal  community  were  highly  diverse,  they 
fell  mainly  into  six  bacterial  groups  with  distinctive 
divisions.  Specifically,  Firmicutes  were  dominant  in 
normal-weight  and  obese  individuals,  but  were 
significantly decreased in post-gastric-bypass individuals, 
who also had a proportional increase of Gammaproteo-
bacteria. Hydrogen-producing Prevotellaceae were highly 
enriched  in  the  obese  individuals.  Unlike  the  highly 
diverse bacteria, the archaea comprised mainly members 
of  the  order  Methanobacteriales,  which  are  hydrogen-
oxidizing  methanogens.  Using  real-time  PCR,  signifi-
cantly  higher  numbers  of  hydrogen-utilizing  methano-
genic archaea were detected in obese individuals than in 
normal-weight  or  post-gastric-bypass  individuals.  The 
authors hypothesized that interspecies hydrogen transfer 
between bacterial and archaeal species is an important 
mechanism  for  increasing  energy  uptake  by  the  large 
intestine in obese persons [95]. It is difficult to definitively 
ascertain whether the surgical trauma, the bypass or the 
altered oral intake is definitively responsible. Nonethe-
less, the inference is that it may be possible to medically 
alter the entire gut microbial make-up of obese patients 
for the purpose of altering energy metabolism and thus 
weight  loss.  More  importantly,  gastric  bypass  patients 
with type II diabetes mellitus are rapidly and definitively 
cured of this condition [96]. Modern bariatric procedures 
therefore represent ‘super system’ surgery that seeks to 
alter the microbiome as part of the surgical procedure for 
the benefit of human health. If the intestinal microbiota 
are involved in this mechanism in some way, and it is 
highly likely that they are, then the treatment of type 2 
diabetes mellitus by microbiotal modulation may repre-
sent an even more valuable drug target than surgery in 
the treatment of obesity.
Significantly, recent evidence suggests that mice geneti-
cally  deficient  in  TLR5,  a  component  of  the  innate 
immune system that is expressed in the gut mucosa and 
that helps defend against infection, exhibit hyperphagia 
and  develop  hallmark  features  of  metabolic  syndrome, 
including hyperlipidemia, hypertension, insulin resis  tance 
and  increased  adiposity  [97].  These  metabolic  changes 
correlated  with  changes  in  the  composition  of  the  gut 
micro  biota, and transfer of the gut microbiota from TLR5-
deficient  mice  to  wild-type  germ-free  mice  con  ferred 
many features of metabolic syndrome to the recipients, 
reciprocating work previously described by Turnbaugh et 
al. [7,98]. This suggests that the altered innate immune 
system may play a direct role in the method of microbial 
modulation of diabetes in the metabolic syndrome.
This theory is supported in part by metabonomic studies 
of  obesity,  because  both  lean  and  obese  animals  have 
specific  metabolic  phenotypes  that  are  linked  to  their 
individual  microbiomes.  The  two  functionally  and 
phenotypically  normal  Zucker  rat  strains  (fa/-  and  -/-) 
were readily distinguished from the (fa/fa) obese rats on 
the basis of their metabotypes, with relatively lower levels 
of urinary hippurate and creatinine, relatively higher levels 
of  urinary  isoleucine,  leucine  and  acetate,  and  higher 
plasma low-density lipoprotein and very low-density lipo-
protein  levels  typifying  the  (fa/fa)  obese  strain  [99]. 
Therefore, if truly personalized strategies that deliver an 
improved quality of care to patients are ever to be delivered 
for  globally  important  health  problems  such  as  obesity, 
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microbial mutualism at genomic, proteomic and metabolic 
levels are urgently required. These approaches will have an 
impact across medicine and surgery, and they will deliver 
the next generation of drug therapies.
Conclusions
Systems  biology  has  irrevocably  altered  the  view  that 
mammalian  metabolism  is  solely  influenced  by  the 
human genome. A core gut microbiome may exist within 
the human gut, at least at a genomic or metabolic level, 
and this is fundamental to the maintenance of health, the 
development of disease and human metabolic processes. 
However,  there  is  a  large  variation  in  the  microbial 
content of the distal gut between individuals and popu-
lations, and it is sensitive to genomic, dietary, age, sex, 
pharmaceutical and even surgical interventions. Systems 
biology approaches at the metabonomic and proteomic 
level  have  greatly  increased  the  potential  of  genomic 
strategies  by  providing  a  ‘functional’  analysis  of  gut 
microbial function, and this suggests that the biological 
mutualism is not only deeper than previously described, 
but  it  may  also  be  modulated  for  the  improvement  of 
human  health.  Next-generation  genomic  technologies 
will lead to the development of experimental models that 
are more representative of the human gut microbiome 
for  hypothesis  testing.  This,  in  turn,  will  expedite  the 
discovery,  testing  and  validation  of  novel  drug  targets. 
However,  a  rapid  resolution  of  the  bottleneck  in  the 
proteomic pipeline is now of the upmost importance if 
this vision is to be realized. Future metagenomic research 
is also likely to center on the complex relationships of the 
gut microbiome with the hundreds of other species of gut 
fungi, viruses, yeasts and parasites so that in time their 
true  importance  to  human  health  will  also  be  better 
understood.  Computational  modeling  of  the  gut  eco-
system  at  a  systems  level  may  yet  permit  advances  in 
cellular engineering technologies that are able to utilize 
the microbiome for drug delivery, production and disease 
prevention  targeted  at  the  individual.  But,  even  before 
this  vision  is  realized,  the  gut  microbiome  will  greatly 
contribute  to  the  delivery  of  personalized  healthcare 
strategies  that  are  already  being  translated  into  the 
clinical environment for the benefit of patients.
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